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Abstract
This cross-sectional study was undertaken to compare health-related quality of life (EQ-5D) in women with and without
undiagnosed Chlamydia trachomatis infection. We analysed data from 2401 multi-ethnic sexually active female students
aged 16–27 years who were recruited to a randomised controlled trial of chlamydia screening – the prevention of pelvic
infection trial in 2004–2006. At recruitment, all participants were asked to provide self-taken vaginal swabs for chlamydia
testing and to complete a sexual health questionnaire including quality of life (EQ-5D). Most women (69%) had an EQ-5D
of one representing ‘perfect health’ in the five dimensions: mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. We therefore compared the proportion of women with an EQ-5D score< 1 implying ‘less than
perfect health’ in women with and without chlamydia infection, and women with symptomatic chlamydia versus the
remainder. The proportion of women with EQ-5D score< 1 was similar in women with and without undiagnosed
chlamydia: 34% (47/138) versus 31% (697/2263; RR 1.11, 95% CI 0.87 to 1.41). However, more women with symptomatic
chlamydia had EQ-5D score< 1 than the remainder: 45% (25/55) versus 31% (714/2319; RR 1.47, CI 1.10 to 1.98). In this
community-based study, EQ-5D scores were similar in women with and without undiagnosed chlamydia. However, a
higher proportion of women with symptomatic chlamydia infection had ‘less than perfect health’. Undiagnosed chlamydia
infection may not have a major short-term effect on health-related quality of life, but EQ-5D may not be the best tool to
measure it in this group.
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Introduction
The 2014 European Centres for Disease Prevention and
Control report called for research on ‘the impact of
chlamydia infection on quality of life to help to provide
more accurate assessments of the cost-eﬀectiveness of
chlamydia screening’.1 Most people with chlamydia
infection have few symptoms, and the eﬀect on
health-related quality of life in the short term is unclear.
EQ-5D scores in people with and without chlamydia
might be useful for exploring the health cost of chla-
mydia and whether screening is worthwhile. It could
also inform wider debates around the impact of chla-
mydia on quality of life. To date, there have been no
UK studies looking at health-related quality of life
associated with chlamydia in sexually active, young,
multi-ethnic women recruited outside healthcare
facilities.
We have baseline cross-sectional EQ-5D scores,
sexual health questionnaires and chlamydia test results
from 2401 women who took part in the prevention of
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pelvic infection (POPI) chlamydia screening trial.2,3
Our aims were:
1. To compare EQ-5D scores in women with and
without undiagnosed chlamydia.
2. To compare EQ-5D scores in women with symptom-
atic chlamydia versus the remainder.
Methods
Data collection
Details of the POPI trial have been published else-
where.2 Brieﬂy, during 2004–2006, a multi-ethnic
sample of 2529 16–27-year-old, sexually active female
students were recruited from 20 universities and further
education colleges in London to a randomised con-
trolled trial to determine whether screening for chla-
mydia reduced the incidence of pelvic inﬂammatory
disease (PID) over the following 12 months. Students
who had never had sexual intercourse and those who
had been tested for chlamydia in the past three months
were excluded from the trial.
Baseline assessment
At baseline, participants were asked to complete a ques-
tionnaire on sexual health and quality of life (EQ5-D
and EQ-VAS), and to provide self-taken vaginal swabs
to test for Chlamydia trachomatis. Participants ran-
domly allocated to the intervention group had their
swabs tested for chlamydia in the next week, and
those with positive tests were referred for treatment.
Samples from participants allocated to the deferred
screening group were frozen at 80C and were
tested after 12 months.2 The sexual health question-
naire was developed by the researchers and included
questions on demographics, number of sexual partners
and on four symptoms that may be associated with
PID: pelvic discomfort, pain during sexual intercourse
abnormal vaginal discharge and bleeding between per-
iods.2 Women who reported all four of these symptoms
were counted as ‘symptomatic’ in the analysis.
Health-related quality of life (EQ-5D)
Questionnaires assessed health-related quality of life
using the EQ-5D tool. This is the preferred method of
utility measurement by the UK National Institute for
Health and Clinical Excellence3 and is generic rather
than disease speciﬁc. The EQ-5D has ﬁve dimensions:
mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. Weighted UK preference values are
linked to the self-reported health state scores for a 0–1
index, where 0 is death and 1 is perfect health.
Sample size
We were limited to the 2529 female students recruited
to the POPI trial2 (Figure 1). Of these, 2401 (95%)
answered questions on health-related quality of life at
baseline and provided samples suitable for chlamydia
testing and were included in the cross-sectional study.
(The questionnaire comprised an A4 sheet with
questions on lifestyle on the ﬁrst page and the EQ-5D
on the second page. It is likely that many of the
128 participants who did not complete EQ-5D did
not turn over the questionnaire before sealing it in the
envelope.)
Statistical analyses
Most participants (69%, 1657/2410) had no problems
with any of the ﬁve dimensions and scored 1 implying
‘perfect health’. We therefore compared the proportion
with EQ-5D index score< 1 (implying ‘less than perfect
health’ in one or more of the ﬁve dimensions) in women
with and without chlamydia infection using relative
risks. We then compared this measure in women with
symptomatic chlamydia versus the remainder. Mean
EQ-5D scores were also estimated.
Results
Sample demographics
Of the 2401 women included in the analysis, 68% were
recruited from universities and the remainder from fur-
ther education (FE) colleges; 27% were of black ethni-
city, 44% were aged less than 20 years and 32% were
smokers. With regard to sexual health at baseline, 41%
reported two or more sexual partners in the preceding
12 months, 30% were aged under 16 at sexual debut,
and 11% reported having an STI in the preceding year.
Forty six per cent reported that they did not use
condoms.
Health-related quality of life scores and
chlamydial infection
Table 1 shows that the proportion of women with EQ-
5D score< 1 was similar in women with and without
undiagnosed chlamydia: 34% versus 31%. However,
more women with symptomatic chlamydia had EQ-
5D score< 1 than the remainder: 45% versus 31%
(p¼ 0.02). (Results were similar if 81 asymptomatic
chlamydia positives who provided details on symptoms
were excluded from the ‘remainder’ group.) Mean EQ-
5D scores were in line with these ﬁndings: 0.88 in those
with symptomatic chlamydia versus 0.95 in the remain-
der (p< 0.01).
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Discussion
Principal findings
In this community-based study, EQ-5D scores were
similar in women with and without undiagnosed chla-
mydia. However, a higher proportion of women with
symptomatic chlamydia had EQ-5D score< 1 than the
remainder.
Strengths and weaknesses
To our knowledge, this is the ﬁrst UK study of health-
related quality of life and chlamydia infection in
sexually active, young, multi-ethnic female students
recruited from a community setting.1 It may be
unique in that women did not know whether or not
they had chlamydia at the time of completing the EQ-
5D. Findings may help to inform wider debates around
the impact of chlamydia on quality of life.
The main limitation is that the EQ-5D was not com-
pleted at time of chlamydia diagnosis. Since partici-
pants did not know if they had chlamydia, the
ﬁndings can only relate to symptoms and not to the
implications of a positive diagnosis with the possible
associated eﬀect on relationships, stigma and anxiety
regarding infertility.4,5 In addition, we did not assess
Figure 1. Flow chart illustrating the number of participants throughout the study.
Table 1. EQ-5D scores in 2401 women with and without undiagnosed chlamydia infection, and in women with symptomatic
chlamydia infection versus the remainder.
EQ-5D< 1
Less than perfect health
EQ-5D¼ 1
Perfect health Relative risk p
Chlamydia positive n¼ 138
(mean EQ-5D .93)
47 (34%) 91 1.11 (0.87 to 1.41) 0.42
Chlamydia negative n¼ 2263
(mean EQ-5D .93)
697 (31%) 1566
Symptomatica chlamydia infection n¼ 55
(mean EQ-5D .88)b
25 (45%) 30 1.47 (1.10 to 1.98) 0.02
No chlamydia or asymptomatic chlamydia n¼ 2319
(mean EQ-5D .95)b
714 (31%) 1605
aTwo women with chlamydia and 25 without chlamydia did not answer the question on symptoms.
bp< 0.01 Wilcoxon rank sum test.
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the eﬀect on quality of life of long-term potential com-
plications of chlamydia such as PID, chronic pelvic
pain, tubal factor infertility or ectopic pregnancy. The
EQ5-D may be less suitable for a young population
who are unlikely to have problems in three of the ﬁve
domains: mobility, self-care and usual activities. We
therefore divided participants into those EQ-5D< 1
versus the remainder. This approach is novel and
might stimulate debate. However, results were similar
using the standard method of EQ-5D analysis. We did
not use data from the EQ-VAS visual analogue scale as
these were skewed. Findings may not be generalisable
and may not apply to other groups such as men in
whom chlamydia infection may be more likely to
cause symptoms. Although the study was completed
almost ten years ago, this is one of the few avail-
able with data on STIs and EQ-5D.3 Finally, these
results only allow us to comment on associations –
we cannot infer any causality from reported EQ-5D
scores.
Comparison with other studies
A previous analysis in the same cohort showed that
women who developed pelvic infection had lower qual-
ity of life scores than those who did not at both baseline
and follow-up. However, pelvic infection did not
appear to reduce EQ-5D scores further.3 By contrast,
most previous studies of the psychological or physical
impact of chlamydia infection have been qualitative
and have focused on participants with a current or
recent diagnosis of chlamydia. Duncan et al.4 found
that women had three main concerns: stigma sur-
rounding the infection, anxiety about future fertility
and apprehension about their partner’s reaction.
Interviews with participants in the CLASS popula-
tion-based screening studies showed similar ﬁndings.5
Interestingly, no one regretted being screened for chla-
mydia. However, there appears to be a paucity of stu-
dies on quality of life related to sexual health in a
student population.1
Finally, some studies6 have used health utility
weights for chlamydia based on the 1999 Institute of
Medicine report.7 Models simulating the natural
history of chlamydia may be combined with cost and
utility data to estimate the number of quality-adjusted
life-years (QALYs) associated with chlamydia.
Economic models estimate the QALYs lost if chla-
mydia is untreated, in order to estimate the QALY
gains associated with treating/preventing chlamydia.
Crucially, these models include potential long-term
sequelae such as tubal infertility. By contrast, our
study focused only on short-term health-related quality
of life.
Implications
Having asymptomatic undiagnosed chlamydia did not
seem to aﬀect EQ-5D scores in the short term in this
group of young women, although symptomatic chla-
mydia was associated with ‘less than perfect’ quality
of life. However, the EQ-5D may not be the best or
most sensitive measure of health-related quality of life
in a young sexually active female population. Issues
around choosing between condition-speciﬁc measures
and generic instruments need further investigation.
Key messages
. EQ-5D scores were similar in women with and with-
out undiagnosed chlamydia infection.
. Women with symptomatic chlamydia infection were
more likely than the remainder to have EQ-5D
score< 1 implying ‘less than perfect health’.
. It is possible that undiagnosed chlamydia infection
does not have a major eﬀect on health-related qual-
ity of life in young women in the short term.
. However, the EQ-5D may not be the best tool to
measure health-related quality of life in sexually
active young women.
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